Company / Operating Income
Amylyx Pharmaceuticals, Inc. Operating Income History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
-$153.3M
FY2025
5-year range
-$314.7M / $38.8M
FY2021-FY2025
Trend
+51.3%
vs FY2024
Sector context
#115 of 204
Health Care
What the data says
At -$153M, Amylyx Pharmaceuticals, Inc.'s operating income ranks #115 of 204 in the Health Care sector. Operating Income has fluctuated over the past 5 years, ranging from -$315M in FY2024 to $39M in FY2023.
Based on SEC 10-K filings.
-$153M in FY2025.
Declined from $39M to -$153M over the past 2 years.
Health Care sector context is included.
Operating Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#115 of 204 in Health CareTop 56% of 204This company -$153.3M Sector average $107.7M
▼
-242.3% below sector average
Key checks
Key Insights
- In FY2025, operating income increased 51.3% year-over-year.
- Ranks #115 out of 204 companies in the Health Care sector.
- Peak operating income was recorded in FY2023.
- Lowest operating income in the period was in FY2024.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$153.3M | +51.3% |
| FY2024 | -$314.7M | -911.1% |
| FY2023 | $38.8M | +119.3% |
| FY2022 | -$201.3M | -143.5% |
| FY2021 | -$82.7M | - |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026